Trans Medics Group, Inc. TMDX
We take great care to ensure that the data presented and summarized in this overview for TransMedics Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TMDX
View all-
Vanguard Group Inc Valley Forge, PA3.64MShares$335 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$243 Million0.01% of portfolio
-
State Street Corp Boston, MA1.36MShares$125 Million0.0% of portfolio
-
Fil LTD Hamilton, D01MShares$92 Million0.06% of portfolio
-
Macquarie Group LTD Australia, C3993KShares$91.3 Million0.07% of portfolio
-
Braidwell LP Stamford, CT922KShares$84.8 Million3.22% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL903KShares$83.1 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V8848KShares$78 Million0.06% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A6828KShares$76.2 Million0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA773KShares$71.1 Million0.0% of portfolio
Latest Institutional Activity in TMDX
Top Purchases
Top Sells
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Insider Transactions at TMDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 03
2025
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,407
-6.26%
|
$182,932
$76.43 P/Share
|
|
Feb 25
2025
|
Waleed H Hassanein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
59,781
+32.99%
|
-
|
|
Feb 24
2025
|
Gerardo Hernandez Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,521
+18.05%
|
-
|
|
Feb 24
2025
|
Anil P. Ranganath |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+27.79%
|
-
|
|
Feb 24
2025
|
Nicholas Corcoran |
BUY
Grant, award, or other acquisition
|
Direct |
12,676
+27.29%
|
-
|
|
Feb 24
2025
|
Tamer I Khayal Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,606
+31.41%
|
-
|
|
Jan 07
2025
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,083
-4.94%
|
$86,640
$80.05 P/Share
|
|
Jan 07
2025
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,083
+4.71%
|
$14,079
$13.28 P/Share
|
|
Dec 09
2024
|
Gerardo Hernandez Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,463
+50.0%
|
-
|
|
Dec 02
2024
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,084
-4.94%
|
$93,224
$86.4 P/Share
|
|
Dec 02
2024
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,084
+4.71%
|
$14,092
$13.28 P/Share
|
|
Nov 11
2024
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,458
-6.54%
|
$131,220
$90.04 P/Share
|
|
Nov 11
2024
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,458
+6.14%
|
$55,404
$38.46 P/Share
|
|
Nov 05
2024
|
Edward M Basile |
SELL
Open market or private sale
|
Direct |
6,750
-68.65%
|
$560,250
$83.83 P/Share
|
|
Nov 05
2024
|
Edward M Basile |
BUY
Exercise of conversion of derivative security
|
Direct |
6,750
+47.43%
|
$189,000
$28.12 P/Share
|
|
Nov 01
2024
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,083
-4.94%
|
$88,806
$82.64 P/Share
|
|
Nov 01
2024
|
Tamer I Khayal Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,083
+4.71%
|
$14,079
$13.28 P/Share
|
|
Oct 15
2024
|
Waleed H Hassanein President & CEO |
SELL
Open market or private sale
|
Direct |
8,625
-3.2%
|
$1,147,125
$133.5 P/Share
|
|
Oct 15
2024
|
Waleed H Hassanein President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,625
+10.93%
|
$112,125
$13.28 P/Share
|
|
Oct 01
2024
|
Tamer I Khayal Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,958
-1.45%
|
$443,700
$150.34 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 117K shares |
|---|---|
| Exercise of conversion of derivative security | 215K shares |
| Bona fide gift | 18K shares |
| Open market or private sale | 267K shares |
|---|---|
| Bona fide gift | 18K shares |